Xconomy Boston

BioVex Garners $30,000,000 Series F Funding

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=ffb186d1-ab19-4295-9783-f0ee4d4c8c77&Preview=1
Date
11/10/2009
Company Name
BioVex
Mailing Address
34 Commerce Way Woburn, MA 01801
Company Description
The Company is developing a new class of potent biologics for the treatment
of cancer and prevention of infectious disease.
Website
http://www.biovex.com
Transaction Type
Venture Equity
Transaction Amount
$30,000,000
Transaction Round
Series F
Proceeds Purposes
The proceeds of the financing will primarily be used to complete the ongoing Phase III pivotal study of OncoVEX (GM-CSF) for the treatment of recurrent and metastatic melanoma and to fund pre-commercialization activities.
M&A Terms
Venture Investor
Morningside Group
Venture Investor
Ventech
Venture Investor
MVM Life Science Partners
Venture Investor
Undisclosed